Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ CD97 Monoclonal Antibody (MEM-180), FITC
Mouse Monoclonal Antibody
Supplier: Invitrogen™ MA119585
Description
This antibody recognizes a unique epitope on CD97, a 75-85 kDa surface glycoprotein of G-protein-coupled receptor family, expressed on activated B and T lymphocytes, monocytes/macrophages, dendritic cells and granulocytes.
CD97 is a G-protein-coupled seven-span transmembrane adhesive receptor that is constitutively expressed on granulocytes and monocytes and rapidly upregulated on T and B cells upon activation. CD97 is produced in alternatively spliced forms and its cellular ligand is CD55 (DAF), which protects various cell types from complement-mediated damage. Interaction of CD97 on leukocytes and CD55 on vessel cells probably facilitate leukocyte activation and migration into the tissues, similarly, CD97 seems to play a role in tumour migration and invasiveness. CD97 is involved in T cell regulation and peripheral granulocyte homeostasis.
Specifications
CD97 | |
Monoclonal | |
FITC | |
ADGRE5 | |
AA409984; Adgre5; adhesion G protein-coupled receptor E5; Cd97; CD97 antigen; CD97 antigen subunit alpha; CD97 antigen subunit beta; CD97 molecule; EGF-TM7 receptor; leukocyte antigen CD97; seven transmembrane helix receptor; seven-span transmembrane protein; seven-transmembrane, heterodimeric receptor associated with inflammation; TM7LN1 | |
Mouse | |
Size-exclusion chromatography | |
RUO | |
976 | |
4°C, store in dark, DO NOT FREEZE! | |
Liquid |
Flow Cytometry | |
MEM-180 | |
PBS with 0.2% BSA and 15mM sodium azide; pH 7.4 | |
P48960 | |
ADGRE5, CD97 | |
PHA-activated PBL. | |
100 Tests | |
Primary | |
Human | |
Antibody | |
IgG1 |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction